Role of Xihuang capsule combined with albumin-bound paclitaxel on the treatment of stage III breast cancer and T cell subsets, survival rate and adverse reactions.

Zhang, Xiaoyu; Li, Huixin; Wu, Feng; Sun, Dan; Zhang, Hengle; Jin, Lijun; Kang, Xiaoning; Wang, Zunyi

Zhang, Xiaoyu; Li, Huixin; Wu, Feng; Sun, Dan; Zhang, Hengle; Jin, Lijun; Kang, Xiaoning; Wang, Zunyi.

Affiliation

Zhang X; Department of Thyroid and Breast III, Cangzhou Central Hospital, Cangzhou, Hebei, China.
Li H; Department of Thyroid and Breast III, Cangzhou Central Hospital, Cangzhou, Hebei, China.
Wu F; Department of Thyroid and Breast III, Cangzhou Central Hospital, Cangzhou, Hebei, China.
Sun D; Department of Thyroid and Breast III, Cangzhou Central Hospital, Cangzhou, Hebei, China.
Zhang H; Department of Thyroid and Breast III, Cangzhou Central Hospital, Cangzhou, Hebei, China/Graduate School of Hebei Medical University, Hebei, China.
Jin L; Department of Thyroid and Breast III, Cangzhou Central Hospital, Cangzhou, Hebei, China.
Kang X; Department of Ultrasound II, Cangzhou Central Hospital, Cangzhou, Hebei, China.
Wang Z; Department of Thyroid and Breast III, Cangzhou Central Hospital, Cangzhou, Hebei, China.

Pak J Pharm Sci ; 36(2(Special)): 619-623, 2023 Mar.

Article in En | MEDLINE | ID: mdl-37548199

Subject(s)

Albumin-Bound Paclitaxel; Breast Neoplasms; Humans; Female; Albumin-Bound Paclitaxel/therapeutic use; Breast Neoplasms/drug therapy; Survival Rate; Paclitaxel/adverse effects; Albumins/adverse effects; T-Lymphocyte Subsets; Antineoplastic Combined Chemotherapy Protocols/adverse effects

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Albumin-Bound Paclitaxel Type of study: Clinical_trials Limits: Female / Humans Language: En Journal: Pak J Pharm Sci Journal subject: FARMACIA / FARMACOLOGIA / QUIMICA Year: 2023 Type: Article Affiliation country: China

Search on Google

XML

PubMed Links